Over $60 billion in venture capital has been invested in synthetic biology companies, making it one of the most heavily funded sectors in deep tech. The 2021 SPAC boom saw Ginkgo Bioworks debut at $15B and Zymergen at $3.4B -- both have since collapsed, forcing a sector-wide reckoning on unit economics. Despite that correction, funding has rebounded: AI-biology convergence is attracting fresh capital to companies like Recursion Pharmaceuticals, Mammoth Biosciences, and Absci. In agriculture, Pivot Bio has raised $618M+ for nitrogen-fixing microbes. Impossible Foods has raised $2B+ for alternative proteins. Below is every major funding round, total raised by company, and the year-over-year trend reshaping synthetic biology investment.
| COMPANY | ROUND | AMOUNT | DATE | VALUATION | LEAD INVESTORS |
|---|---|---|---|---|---|
| ArsenalBio | Series C | $630M | 2024/01 | Undisclosed | Westlake Village BioPartners |
| National Resilience | Series B | $625M | 2022/03 | $4.6B | Flagship Pioneering, a16z Bio |
| Sana Biotechnology | IPO | $588M | 2021/02 | $8.6B (peak post-IPO) | Goldman Sachs, J.P. Morgan |
| Pivot Bio | Series D | $430M | 2021/08 | $2B+ | DCVC, Breakthrough Energy Ventures, Temasek |
| Generate Biomedicines | Series B | $370M | 2022/05 | Undisclosed | T. Rowe Price, Fidelity |
| Solugen | Series D | $357M | 2022/08 | $2B+ | GIC, Baillie Gifford |
| Perfect Day | Series D | $350M | 2021/09 | $1.5B+ | Temasek, Canada Pension Plan |
| Spiber | Series F | $312M | 2023/07 | Undisclosed | Carlyle Group |
| Caribou Biosciences | IPO | $304M | 2021/07 | $1B+ (initial) | J.P. Morgan, Cowen |
| Bolt Threads | Series E | $253M | 2021/09 | Undisclosed | Baillie Gifford, Fidelity |
HQ: Boston, MA, USA · CEO: Jason Kelly
HQ: San Diego, CA, USA · CEO: Rahul Singhvi
HQ: Zug, Switzerland / Cambridge, MA, USA · CEO: Samarth Kulkarni
HQ: Emeryville, CA, USA (formerly) · CEO: N/A (acquired)
HQ: Salt Lake City, UT, USA · CEO: Chris Gibson
HQ: Cambridge, MA, USA · CEO: John Leonard
HQ: Seattle, WA, USA · CEO: Steve Harr
HQ: South San Francisco, CA, USA · CEO: Emily Leproust
HQ: South San Francisco, CA, USA · CEO: Ken Drazan
HQ: Berkeley, CA, USA · CEO: Ryan Pandya
| COMPANY | TICKER / STATUS | CATEGORY | MARKET CAP / VAL | NOTE |
|---|---|---|---|---|
| Ginkgo Bioworks | NYSE: DNA | Platform | ~$420M | Largest cell programming platform. SPAC at $15B (2021), significant compression. Acquired Zymergen 2022. |
| Twist Bioscience | NASDAQ: TWST | DNA Synthesis | ~$2B | Dominant synthetic DNA provider. Revenue growing toward breakeven. |
| Mammoth Biosciences | Private | CRISPR / Diagnostics | $3B+ val (2022) | Co-founded by Jennifer Doudna. CRISPR diagnostics and therapeutics. |
| Recursion Pharmaceuticals | NASDAQ: RXRX | AI Drug Discovery | Public | AI-driven drug discovery with massive biological dataset. TechBio leader. |
| Pivot Bio | Private | Agriculture | $618M+ raised | Nitrogen-fixing microbes replacing synthetic fertilizer. Commercial product. |
| Impossible Foods | Private | Food | $2B+ raised | Plant-based and precision fermentation meat alternatives. IPO candidate. |
| Bolt Threads | Private | Materials | $319M raised | Spider silk (Microsilk) and mycelium leather (Mylo). Partnership with Stella McCartney. |
| Inari | Private | Seed Engineering | $400M+ raised | Gene editing for crop improvement. Multiplex editing technology. |
| YEAR | TOTAL RAISED | ROUNDS | LARGEST ROUND |
|---|---|---|---|
| 2019 | $3.8B | 120+ | Impossible Foods ($300M Series E) |
| 2020 | $7.7B | 180+ | Ginkgo Bioworks ($300M Series E) |
| 2021 | $18B+ | 300+ | Multiple SPACs: Ginkgo ($15B), Zymergen ($3.4B), Amyris |
| 2022 | $10B | 200+ | Pivot Bio ($430M Series D) |
| 2023 | $5B | 150+ | Mammoth Biosciences ($200M Series D) |
| 2024 | $6B+ | 160+ | AI-biology convergence rounds (Recursion, Absci) |
| 2025 | $7B+ | 170+ | Inari ($200M+), multiple TechBio rounds |
| 2026 YTD | $2B+ | 40+ | Early-stage AI-bio and ag-biotech rounds |
DISCLAIMER: This is market intelligence, not investment advice. Do your own research.
Synthetic biology venture capital has undergone a dramatic arc: from the $18B peak of 2021 (fueled by SPACs and pandemic-era biotech enthusiasm) through the 2022-2023 reckoning (Amyris bankrupt, Zymergen acquired at 90% discount) to the current AI-biology convergence renaissance. The sector is healthier for the correction -- investors now demand unit economics and revenue traction, not just platform narratives. The strongest capital magnets in 2025-2026 are companies combining biological data with AI models (Recursion, Absci), agriculture biotech with commercial products (Pivot Bio, Inari), and CRISPR therapeutics with approved drugs (CRISPR Therapeutics, Mammoth Biosciences). The next wave of IPOs will test whether public markets have regained appetite for synbio after the Ginkgo and Amyris experiences. The $60B+ invested to date reflects genuine conviction that engineered biology will become a multi-trillion-dollar platform -- but the path from lab to commercial scale remains the sector's defining challenge.